Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 87,989
  • Shares Outstanding, K 75,853
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,560 K
  • 60-Month Beta 1.91
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.18
Trade ONCY with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.08
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0200 +10.78%
on 04/18/24
1.2801 -11.73%
on 05/09/24
+0.0500 (+4.63%)
since 04/16/24
3-Month
0.8855 +27.61%
on 03/04/24
1.2900 -12.40%
on 04/04/24
-0.0300 (-2.59%)
since 02/16/24
52-Week
0.8830 +27.97%
on 02/07/24
3.3942 -66.71%
on 06/23/23
-0.5000 (-30.67%)
since 05/16/23

Most Recent Stories

More News
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the...

ONCY : 1.1300 (-2.59%)
ONC.TO : 1.55 (-1.27%)
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection

/CNW/ -- USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood test can...

ONCY : 1.1300 (-2.59%)
CADL : 12.70 (-9.29%)
ABVC : 1.0600 (-1.85%)
CTMX : 2.0000 (+2.04%)
AMGN : 314.72 (-1.35%)
ONC.TO : 1.55 (-1.27%)
Biotech Innovations Drive Hope in Global Fight Against Pancreatic Cancer

USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood test can accurately detect early-stage pancreatic cancer with...

ONCY : 1.1300 (-2.59%)
ONC.TO : 1.55 (-1.27%)
CADL : 12.70 (-9.29%)
ABVC : 1.0600 (-1.85%)
CTMX : 2.0000 (+2.04%)
AMGN : 314.72 (-1.35%)
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that...

ONCY : 1.1300 (-2.59%)
ONC.TO : 1.55 (-1.27%)
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced...

ONCY : 1.1300 (-2.59%)
ONC.TO : 1.55 (-1.27%)
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:ZLAB),(NASDAQ:NTBL),(NASDAQ:CRDF),(NYSE:JNJ) EQNX::TICKER_END

ONCY : 1.1300 (-2.59%)
ONC.TO : 1.55 (-1.27%)
ZLAB : 19.93 (-4.41%)
NTBL : 1.0400 (-3.70%)
CRDF : 3.74 (+4.76%)
JNJ : 154.28 (+1.05%)
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

US$5 million PanCAN grant provides important support for the fifth cohort of the GOBLET study   Study of modified FOLFIRINOX/pelareorep/atezolizumab (Tecentriq ® ) combination expands existing pancreatic...

ONCY : 1.1300 (-2.59%)
ONC.TO : 1.55 (-1.27%)
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

/CNW/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding...

ONCY : 1.1300 (-2.59%)
CADL : 12.70 (-9.29%)
AZN : 77.04 (+0.09%)
HALO : 45.39 (-0.94%)
JANX : 47.51 (+0.06%)
ONC.TO : 1.55 (-1.27%)
Rising Cancer Rates Drive Biotech Advancements Despite Political Hurdles

USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden’s “Cancer...

ONCY : 1.1300 (-2.59%)
ONC.TO : 1.55 (-1.27%)
CADL : 12.70 (-9.29%)
AZN : 77.04 (+0.09%)
HALO : 45.39 (-0.94%)
JANX : 47.51 (+0.06%)
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will commence...

ONCY : 1.1300 (-2.59%)
ONC.TO : 1.55 (-1.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated...

See More

Key Turning Points

3rd Resistance Point 1.2133
2nd Resistance Point 1.1967
1st Resistance Point 1.1633
Last Price 1.1300
1st Support Level 1.1133
2nd Support Level 1.0967
3rd Support Level 1.0633

See More

52-Week High 3.3942
Fibonacci 61.8% 2.4349
Fibonacci 50% 2.1386
Fibonacci 38.2% 1.8423
Last Price 1.1300
52-Week Low 0.8830

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar